Treace Medical (TMCI) Reports Five-Year Bunion Results. Can Evidence Drive Adoption?
Jeff LewisWed, September 23, 2026 at 3:38 AM GMT+3 3 min read
Treace Medical Concepts, Inc. (NASDAQ:TMCI) announced five-year ALIGN3D results on September 17, adding longer-term evidence for the Lapiplasty bunion-correction procedure. The final analysis included 137 of 173 treated patients, or approximately 79% of the original group.
Reported radiographic recurrence was 0.8% when defined as a hallux valgus angle greater than 20 degrees and 5.3% using a threshold greater than 15 degrees. That angle measures big-toe misalignment on an X-ray. Both figures matter because the definition determines which cases count as recurrence.
Treace Medical Concepts, Inc. (NASDAQ:TMCI) also reported clinically meaningful improvements in patient-reported outcomes maintained through five years. The commercial question is whether this evidence can persuade more surgeons to adopt Lapiplasty and increase repeat use.
Bull Case
Five years of follow-up addresses an important concern in bunion surgery: whether correction lasts. For Treace Medical Concepts, Inc. (NASDAQ:TMCI), sustained alignment and patient-reported improvement provide a stronger foundation for surgeon education than early postoperative results alone.
ALIGN3D was a company-funded, prospective, multicenter study without a comparison group, involving seven U.S. sites and 13 surgeons. That gives the evidence breadth beyond one surgeon's practice, although patient selection still matters when applying the findings elsewhere.
Lapiplasty combines instruments, implants, and a surgical technique designed to correct the deformity in three dimensions and stabilize the affected joint. Durable results could help Treace Medical Concepts, Inc. (NASDAQ:TMCI) explain the value of that approach to surgeons evaluating competing systems.
Existing surgeon relationships provide a commercial starting point. In the second quarter, approximately 40% of Lapiplasty surgeon users incorporated at least one of three newer bunion systems, up from 35% in the first quarter. That adoption predates the five-year announcement, but suggests opportunities to deepen usage across the broader portfolio.
Bear Case
The disclosed analysis does not establish superiority over competing procedures through a randomized comparison. Differences in patient characteristics, surgical technique, and recurrence definitions make comparisons with unrelated studies difficult.
Four-year follow-up and complication details have already been published. The final five-year analysis did not include 36 of the 173 treated patients. Their absence does not establish poor outcomes, but their results could affect the interpretation of durability. Reasons for missing follow-up and endpoint-specific patient counts in the final five-year dataset would help investors assess the evidence.
Radiographic recurrence is also distinct from complications, repeat surgery, and overall patient satisfaction. Assessment of Treace Medical Concepts, Inc. (NASDAQ:TMCI) requires the final five-year complication and healing outcomes alongside the headline recurrence rates.
Commercial performance remains the harder test. Treace Medical Concepts, Inc. (NASDAQ:TMCI) reported second-quarter revenue of $45.4 million, down 4%, despite management reporting case-volume growth. Gross margin declined to 78.5% from 79.7%, while the GAAP net loss was $15.9 million. Stronger clinical evidence must translate into revenue and profitable utilization to improve the investment case.
Hedge Fund Sentiment
The filings available so far reflect positions held before Treace Medical Concepts, Inc. (NASDAQ:TMCI) announced its five-year ALIGN3D results. Insider Monkey's database showed 18 hedge funds holding Treace Medical Concepts, Inc. (NASDAQ:TMCI) at the end of 2Q2026, up from 10 funds three months earlier.
Conclusion
Treace Medical Concepts, Inc. (NASDAQ:TMCI) has strengthened the durability case for Lapiplasty. The evidence supports surgeon engagement, while comparative effectiveness and commercial returns remain separate questions. Fuller disclosure of final five-year follow-up and complications, sustained procedure growth, repeat surgeon usage, and improving margins would make the adoption thesis more compelling.
While we acknowledge the potential of TMCI as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on thebest short-term AI stock.
READ NEXT: Korn Ferry (KFY) Grew Contracted Fees 14%. Can AMS Add Growth Without Squeezing Margins? and Mastercard (MA) Partners With Flowcart. Can In-Chat Payments Deliver Profitable Growth?
This article is originally published at Insider Monkey.
Yorumlar (0)
Giriş yaparak yorum yazabilirsin.
İlk yorumu sen yaz.